IP Library Granted Patent US 8,507,658
Granted Patent B2
US 8,507,658 · App. 13/373,428 · Granted Aug 13, 2013

Ex vivo animal or challenge model as method to measure protective immunity directed against parasites and vaccines shown to be protective in the method

Inventors: Florine Johanna van Milligen (Abcoude, NL); Johannes Bernardus Wilhelmus Joseph Cornelissen (Dronten, NL); Bernard Adri Bokhout (Ermelo, NL)
Assignee: Stichting Dienst Landbouwkundig Onderzoek
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,507,658
App. No.
13/373,428
Granted
Aug 13, 2013
Kind
B2
Abstract

Described are antibodies specifically directed against a cathepsin-like protease that are specific for newly excysted juvenile (NEJ) stages of Fasciola hepatica . Diagnostic tests wherein such antibodies are detected or used are also provided.

Claims (25)

1. An isolated or synthetic antibody specifically directed against a proregion of a cathepsin-like protease obtained from excretory/secretory products of newly excysted juvenile (NEJ) stages of Fasciola hepatica , wherein the proregion consists of a peptide comprising the amino acid sequence SEQ ID NO:1, an amino acid sequence consisting of at least 85% sequence identity with SEQ ID NO: 24, or an amino acid sequence consisting of at least 85% sequence identity with SEQ ID NO: 26.

2. The antibody of claim 1 , wherein the Fasciola hepatica is of the type that infects a host through a mucosal or skin surface.

3. A composition comprising the antibody of claim 1 .

4. A method for performing a diagnostic test for detecting a cathepsin-like protease obtained from excretory/secretory products of newly excysted juvenile (NEJ) stages of Fasciola hepatica , the method comprising contacting a serum sample from a subject with the antibody of claim 1 .

5. The method according to claim 4 , further comprising:

contacting the serum sample with at least one Fasciola hepatica protein or antigenic fragment thereof; and

detecting an antibody directed against Fasciola hepatica , excluding the antibody of claim 1 ,

wherein the diagnostic test is specifically designed to be utilized as an accompanying test to the utilization of a vaccine directed against Fasciola hepatica that specifically includes a peptide from a proregion of a cathepsin-like protease obtained from excretory/secretory products of newly excysted juvenile (NEJ) stages of Fasciola hepatica.

6. The method according to claim 4 , further comprising:

contacting the serum sample with at least one antibody directed against Fasciola hepatica , excluding the antibody of claim 1 ; and

detecting a Fasciola hepatica protein or antigenic fragment thereof, excluding a cathepsin-like protease obtained from excretory/secretory products of newly excysted juvenile (NEJ) stages of Fasciola hepatica,

wherein the diagnostic test is specifically designed to be utilized as an accompanying test to the utilization of a vaccine directed against Fasciola hepatica that specifically includes a peptide from a proregion of a cathepsin-like protease obtained from excretory/secretory products of newly excysted juvenile (NEJ) stages of Fasciola hepatica.

7. A method for performing a diagnostic test for detecting an antibody according to claim 1 comprising contacting a serum sample with a cathepsin-like protease obtained from excretory/secretory products of newly excysted juvenile (NEJ) stages of Fasciola hepatica.

8. The method according to claim 7 , further comprising:

contacting the serum sample with at least one Fasciola hepatica protein or antigenic fragment thereof; and

detecting an antibody directed against Fasciola hepatica , excluding the antibody of claim 1 ,

wherein the diagnostic test is specifically designed to be utilized as an accompanying test to the utilization of a vaccine directed against Fasciola hepatica that specifically includes a peptide from a proregion of a cathepsin-like protease obtained from excretory/secretory products of newly excysted juvenile (NEJ) stages of Fasciola hepatica.

9. The method according to claim 7 , further comprising:

contacting the serum sample with at least one antibody directed against Fasciola hepatica , excluding the antibody of claim 1 ; and

detecting a Fasciolas hepatica protein or antigenic fragment thereof, excluding a cathepsin-like protease obtained from excretory/secretory products of newly excysted juvenile (NEJ) stages of Fasciola hepatica,

wherein the diagnostic test is specifically designed to be utilized as an accompanying test to the utilization of a vaccine directed against Fasciola hepatica that specifically includes a peptide from a proregion of a cathepsin-like protease obtained from excretory/secretory products of newly excysted juvenile (NEJ) stages of Fasciola hepatica.

10. The method according to claim 4 , wherein the at least one Fasciola hepatica protein or antigenic fragment thereof is a recombinant protein.

11. The method according to claim 4 , wherein the Fasciola hepatica is of the type that infects a host through a mucosal or skin surface.

12. The method according to claim 7 , wherein the at least one Fasciola hepatica protein or antigenic fragment thereof is a recombinant protein.

13. The method according to claim 7 , wherein the Fasciola hepatica is of the type that infects a host through a mucosal or skin surface.

Assignments (2)
CHANGE OF NAME Recorded Oct 6, 2016
From: STICHTING DIENST LANDBOUWKUNDIG ONDERZOEK
To: STICHTING WAGENINGEN RESEARCH
Reel/Frame 039959/0338 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2011
From: VAN MILLIGEN, FLORINE J.; CORNELISSEN, JOHANNES B. W. J.; BOKHOUT, BERNARD A.
To: STICHTING DIENST LANDBOUWKUNDIG ONDERZOEK
Reel/Frame 027377/0697 →
Priority Claims (1)
EP 97200730 · Mar 11, 1997 · regional
Continuity (5)
Continuation 12800205 · May 10, 2010
Division 11881598 · Jul 26, 2007
Continuation 10382479 · Mar 6, 2003
Continuation 09381122 · Dec 23, 1999
Related Publication 20120107342A1 · May 3, 2012